Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EVAGELOS COSKINAS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1437382314
CMS profile
201763
Location
RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$75.07

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $75.07 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Otsuka America Pharmaceutical, Inc. $75.07 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EVAGELOS COSKINAS

NPI 1437382314 · CMS profile ID 201763

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

RIVERSIDE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437382314?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437382314?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437382314?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
EVAGELOS COSKINAS, NPI 1437382314, CMS profile ID 201763, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1437382314?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $75.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $25.1206/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014289561 CMS
Otsuka America Pharmaceutical, Inc. $23.2603/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014289553 CMS
Otsuka America Pharmaceutical, Inc. $26.6902/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014289545 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $92.48 5
PY2020 $28.27 1
PY2021 $85.12 1
PY2022 $87.50 1
PY2023 $75.07 3
PY2024 $497.65 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,435,713.44 192
PY2024 Principal investigator $1,112,891.48 274
PY2023 Principal investigator $145,338.68 81
PY2021 Principal investigator $14,588.05 4
PY2020 Principal investigator $129,452.46 74
PY2019 Principal investigator $432,130.59 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

274 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $840.00 12/31/2024 Non-covered Recipient Entity
CITRIALS
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100764103
Principal investigator 1 ABBVIE INC. $742.00 12/31/2024 Non-covered Recipient Entity
CITRIALS
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1100764105
Principal investigator 1 ABBVIE INC. $1,000.00 12/18/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100761729
Principal investigator 1 ABBVIE INC. $2,845.54 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760937
Principal investigator 1 ABBVIE INC. $1,500.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760939
Principal investigator 1 ABBVIE INC. $1,000.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760941
Principal investigator 1 ABBVIE INC. $860.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760943
Principal investigator 1 ABBVIE INC. $1,300.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760957
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152607
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152611
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152615
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152619
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152622
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152626
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152630
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152634
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152638
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152641
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152644
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152648
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152652
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152656
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152660
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152663
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152667
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152671
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152674
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152678
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152682
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152686
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152689
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152693
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152697
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152701
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152705
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152708
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152712
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152716
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152720
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152723
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152727
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152735
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152738
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,897.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152742
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152746
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 12/11/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143152750
Principal investigator 1 ABBVIE INC. $9,486.60 11/20/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100755899
Principal investigator 1 ABBVIE INC. $7,484.24 11/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100755063
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 11/07/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144239098
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145488
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145492
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145496
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145500
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145504
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145507
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145511
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145515
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145518
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145522
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145526
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145530
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145533
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145537
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145541
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145545
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145548
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145552
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145555
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145559
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145563
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145566
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145570
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145574
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145577
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145581
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145585
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145588
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145592
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145596
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145600
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145604
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145607
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145611
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145615
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145619
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145622
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145626
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145630
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145634
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145637
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145641
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145645
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145648
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145652
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145656
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145659
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145662
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145666
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145670
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145674
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145677
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145681
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145685
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145688
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145692
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145696
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145700
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145704
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145708
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145711
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145715
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145719
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145723
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145726
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145730
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145734
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145737
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145741
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145745
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145749
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145752
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145756
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145760
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145763
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145767
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145771
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145775
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145779
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145782
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145786
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145790
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145794
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145797
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145801
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145805
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145808
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145812
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145816
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145820
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145824
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145827
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145831
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145835
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145839
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145842
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145846
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145850
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145854
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145857
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145861
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145865
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145869
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145872
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145876
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145880
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145884
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145888
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145892
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145896
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145899
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145903
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145908
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145912
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145916
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145920
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145923
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 11/06/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143145927
Principal investigator 1 ABBVIE INC. $1,147.90 11/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100751573
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $338.00 10/16/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143139108
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 10/16/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143139112
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138537
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138541
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138545
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138549
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138552
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138556
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138560
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,966.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138564
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,497.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138567
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,897.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138571
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138575
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138579
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138582
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138586
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138590
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138593
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138597
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138601
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138605
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138608
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138612
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138616
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 10/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143138620
Principal investigator 1 ABBVIE INC. $349.70 10/02/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100745086
Principal investigator 1 ABBVIE INC. $12,286.70 10/02/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100745088
Principal investigator 1 ABBVIE INC. $22,821.60 10/02/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100745090
Principal investigator 1 ABBVIE INC. $12,221.70 10/02/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100745138
Principal investigator 1 ABBVIE INC. $68,350.00 10/02/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100745140
Principal investigator 1 ABBVIE INC. $603.20 09/25/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100743884
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134204
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134208
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134211
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134215
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134219
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134223
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134226
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134230
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,897.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134234
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,897.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134237
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $393.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134241
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134245
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134249
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134253
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134257
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134260
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134264
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134268
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134272
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134276
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134279
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134283
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134287
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134291
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134295
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134299
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134303
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134307
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134310
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134314
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134318
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $90.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134322
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $41.00 09/23/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143134326
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,400.00 09/19/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143133146
Principal investigator 1 ABBVIE INC. $65,029.29 09/18/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100743114
Principal investigator 1 ABBVIE INC. $7,493.20 09/18/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100743116
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,331.78 09/18/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144239060
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,661.55 09/18/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144239084
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143130110
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143130114
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143130117
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 09/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143130121
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $473.00 09/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143130125
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,200.00 09/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143129577
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,514.00 09/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143129581
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,529.00 09/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143129584
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 09/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143129588
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 09/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143129592
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,750.00 09/04/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143129595
Principal investigator 1 ABBVIE INC. $600.00 08/14/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100736158
Principal investigator 1 ABBVIE INC. $600.00 08/14/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100736160
Principal investigator 1 Axsome Therapeutics, Inc. $450.00 08/14/2024 Non-covered Recipient Entity
Clinical Innovations Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148256571
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,986.00 08/14/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
ITI-007-451 No dispute reported 06/30/2026 1143128987
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,351.35 07/25/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143127790
Principal investigator 1 Axsome Therapeutics, Inc. $3,454.16 06/20/2024 Non-covered Recipient Entity
Clinical Innovations Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148256555
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $640.70 06/20/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144239040
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $113,457.31 05/20/2024 Non-covered Recipient Entity
Cenexel Cit
Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) No dispute reported 06/30/2026 1123476454
Principal investigator 1 Axsome Therapeutics, Inc. $755.00 05/16/2024 Non-covered Recipient Entity
Clinical Innovations Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148256559
Principal investigator 1 Axsome Therapeutics, Inc. $75.68 04/16/2024 Non-covered Recipient Entity
Clinical Innovations Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148256565
Principal investigator 1 Sumitomo Pharma America, Inc. $554.00 04/03/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) No dispute reported 06/30/2026 1148437164
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 03/29/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC CENEXEL
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication No dispute reported 06/30/2026 1148437081
Principal investigator 1 Sumitomo Pharma America, Inc. $1,701.00 03/13/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication No dispute reported 06/30/2026 1148437180
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 02/29/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC CENEXEL
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication No dispute reported 06/30/2026 1148437079
Principal investigator 1 Axsome Therapeutics, Inc. $6,200.00 02/27/2024 Non-covered Recipient Entity
Clinical Innovations Inc.
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1148256551
Principal investigator 1 Sumitomo Pharma America, Inc. $680.00 02/14/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) No dispute reported 06/30/2026 1148437168
Principal investigator 1 Sumitomo Pharma America, Inc. $24,709.50 02/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication No dispute reported 06/30/2026 1148437176
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,036.39 02/07/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238944
Principal investigator 1 Sumitomo Pharma America, Inc. $40.00 02/05/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) No dispute reported 06/30/2026 1148437166
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 01/31/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC CENEXEL
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication No dispute reported 06/30/2026 1148437077
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,323.66 01/18/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143123888
Principal investigator 1 Sumitomo Pharma America, Inc. $23,372.10 01/10/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication No dispute reported 06/30/2026 1148437172
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $303.80 01/09/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238946
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,034.20 01/08/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1143123443
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,256.63 01/05/2024 Non-covered Recipient Entity
CLINICAL INNOVATIONS INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1144238942